Severe community-acquired pneumonia due to *Streptococcus pyogenes* in the Newcastle area

Paul A Wilson, Hemalatha Varadhan

# Abstract

## Background

An apparent increase in the incidence of severe community-acquired pneumonia (CAP) caused by Streptococcus pyogenes (group A Streptococcus – GAS) was observed during 2017 in the Newcastle area. The study was undertaken to establish whether there was a true increase in severe S. pyogenes pneumonia and to explore its epidemiology and clinical features.

## Methods

The study was a retrospective descriptive study of S. pyogenes pneumonia set in two tertiary referral hospitals in Newcastle, a large regional city, during the period 2007 to 2018. Subjects were adults identified as having S. pyogenes pneumonia by searching a database of severe CAP (defined as requiring intensive care unit [ICU] admission) for the period 2007–2018. Laboratory records were also searched for sterile site isolates of S. pyogenes to identify patients not requiring ICU admission.

## Results

There were 13 cases of S. pyogenes CAP identified during the study period, of whom 12 (92%) required ICU admission. S. pyogenes accounted for 12/728 (1.6%) cases of severe CAP during the study period. The severity of S. pyogenes pneumonia was high despite a mean patient age of 48 years and 7/13 (54%) having no significant past medical history. The mortality rate was 2/13 (15%). Viral co-infection was found in 6/12 (50%) of patients tested. Overall 7/12 (58%) of the patients with severe S. pyogenes CAP during the study period presented in the winter or spring of 2017.

## Conclusions

Streptococcus pyogenes is a rare cause of severe CAP in the Newcastle area, but there was a marked increase in frequency observed during the 2017 influenza season. Further study of the epidemiology of invasive GAS (iGAS) disease in Newcastle is warranted to identify emerging trends in this severe infection.

Keywords: community-acquired pneumonia, Streptococcus pyogenes, Newcastle

# Introduction

Streptococcus pyogenes commonly causes localised illness such as pharyngitis and skin/soft tissue infections (e.g. impetigo, cellulitis); it sometimes causes asymptomatic colonisation. S. pyogenes also causes invasive diseases which include bacteraemia, pneumonia, necrotising fasciitis and streptococcal toxic shock syndrome. During the early 20th century, prior to the introduction of antibiotics, S. pyogenes caused about 2–5% of bacterial pneumonia.1 Large outbreaks of S. pyogenes pneumonia were sometimes seen as complications of respiratory virus infections such as influenza and measles.1 S. pyogenes pneumonia has since become a relatively rare disease, with recent publications largely limited to case reports, small case series, reviews of recent literature and larger series of invasive S. pyogenes infections of all types (Table 1). The latter include studies from Victoria and Western Sydney as well as tropical Australia (Northern Territory, north Queensland)2–7 (Table 2).

Table 1: Published case series of *Streptococcus pyogenes* pneumonia

| Refa | Years | Site | Patients | Ageb | Mortality | Viral coinfection | Previously well |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 15 | 1987–2016 | all | 16 | 42 | 38% | 25%c | 63% |
| 16 | 1981–1997 | UK | 17 | 57 | 47% | 6%d | 35% |
| 17 | 2006–2015 | Spain | 40 | 60 | 20% | 10%e | 32% |
| 20 | 2010–2011 | UK | 10 | NSf | 80% | 40%g | 60% |
| 21 | 2009 | USA | 9 | 37 | 66% | 100%h | 56% |

a Reference.

b Mean age.

c 1 influenza A, 3 influenza B.

d 1 influenza A.

e 3 influenza A, 1 influenza B.

f Not stated.

g 1 influenza A, 3 influenza B.

h 9 influenza A (H1N1)

Table 2: Invasive GAS infection (iGAS) in Australia: reported case series

| Refa | Time period | Location | iGAS cases | Pneumonia | Incidence per 100,000 | Mortality |
| --- | --- | --- | --- | --- | --- | --- |
| 2 | 1996–2001 | North Queensland | 109 | 10 (9%) | 82.5 (Aboriginal and Torres Strait Islander)10.1 (Non-Indigenous) | 7% |
| 3 | 2002–2004 | Victoria | 333 | 36 (10.8%) | 2.7 | 7.8% |
| 4 | 1998–2009 | Northern Territory (“Top End”) | 295 | 8 (6.6%) | 15.8 (all)40.6 (Aboriginal and Torres Strait Islander) | 13.8% |
| 5 | 2011–2013 | Northern Territory | 128 | 12 (9%) | 8.8 (Non-Indigenous)69.7 (Aboriginal and Torres Strait Islander) | 8% |
| 6 | 2007–2017 | Victoria | 1,311 | NSb | 2.1 | NSb |
| 7 | 2008–2010 | Western Sydney, New South Wales | 72 | 2 (2.8%)c | NSb | 8.3% |

a Reference.

b Not stated.

c Empyema.

During the winter and early spring of 2017, it was noticed that there were a number of patients presenting to public hospitals in Newcastle, New South Wales, with severe community-acquired pneumonia due to Streptococcus pyogenes. The current study was performed in order to assess whether there was a true increase in the local incidence of S. pyogenes pneumonia, and to describe its clinical features in a local population. A secondary aim was to determine the frequency of viral co-infection in these patients.

Table 3: Severe *Streptococcus pyogenes* pneumonia in the Newcastle area

| Year | Number of cases | % of total |
| --- | --- | --- |
| 2007 | 1 | 8.3 |
| 2008 |  |  |
| 2009 |  |  |
| 2010 | 2 | 16.7 |
| 2011 |  |  |
| 2012 |  |  |
| 2013 |  |  |
| 2014 | 1 | 8.3 |
| 2015 | 1 | 8.3 |
| 2016 |  |  |
| 2017 | 7 | 58.3 |
| 2018 |  |  |

Table 4: Influenza in NSW and Hunter New England (HNE) LHDa

| Year | Influenzatotal NSW | Flu A | Flu B | HNE LHDcases | HNE LHDincidence per 100,000 |
| --- | --- | --- | --- | --- | --- |
| 2009 |  | 1,298b |  |  |  |
| 2010 |  | 546 | 93 |  |  |
| 2011 |  | 2,438 | 1,215 |  |  |
| 2012 |  | 4,365 | 1,263 |  |  |
| 2013 |  | 3,716 | 2,404 |  |  |
| 2014 |  | 15,672 | 2,553 |  |  |
| 2015 |  | 10,513 | 18,978 | 2,643 | 291 |
| 2016 | 35,409 | 32,391 | 3,797 | 3,264 | 356.2 |
| 2017 | 102,880 | 59,468 | 42,841 | 11,968 | 1287.2 |
| 2018 | 17,467 | 13,625 | 3,051 | 1,819 | 194.1 |

a NSW = New South Wales; LHD = Local Health District.

b May to December.

# Methods

## Setting, data collection

A database was maintained of episodes of severe community-acquired pneumonia, as defined by the requirement for intensive care unit (ICU) admission, at each of two tertiary referral centres in Newcastle (John Hunter Hospital and Calvary Mater Newcastle) during the period 1 January 2007 to 31 December 2018. The data were collected using a combination of prospective and retrospective methods. Information recorded in a spreadsheet included demographic details such as age, sex, comorbidities; clinical characteristics including requirement for inotropic support or mechanical ventilation, presence of acute kidney injury, length of hospital stay; and diagnostic information such as chest x-ray findings, inflammatory markers (C-reactive protein, procalcitonin) and tests for etiology of pneumonia (blood and sputum cultures, urinary Legionella and pneumococcal antigens, multiplex respiratory virus nucleic acid amplification tests [NAAT], pleural fluid culture and NAAT). The multiplex respiratory virus NAAT (Ausdiagnostics, Mascot, Australia) was available from 2012 and tested for influenza, parainfluenza, respiratory syncytial virus (RSV), adenovirus, picornavirus and human metapneumovirus. Prior to 2012, influenza was tested by NAAT and the other viruses by direct fluorescent antibody testing (DFA). The investigation of pneumonia etiology and the choice of diagnostic tests was directed by the treating team. A search was made for further patients with S. pyogenes pneumonia who were not admitted to ICU by searching the NSW Health Pathology database for positive blood cultures for S. pyogenes, which were cross-checked with admission chest x-ray reports. The study included only adult patients (aged ≥ 18 years). S. pyogenes was identified using Gram stain followed by serologic antigen testing and MALDI-TOF mass spectrometry (VITEK MS, bioMerieux).

## Definitions

The diagnosis of community-acquired pneumonia was confirmed by the following: a chest x-ray report of a new pulmonary infiltrate documented within 24 hours of hospital admission; a clinical diagnosis of community-acquired pneumonia by the treating team; and clinical and/or laboratory findings consistent with infection. The following criteria were used to define S. pyogenes as the cause of community acquired pneumonia: positive blood or pleural fluid culture, or pleural fluid NAAT.

# Results

## Patient characteristics

For the 12-year period from 1 January 2007 to 31 December 2018, a total of 213 adult patients with positive blood cultures for S. pyogenes were identified by searching the NSW Health Pathology database. There were 13 identified cases of community-acquired pneumonia due to S. pyogenes in adults, of whom all except one had severe CAP requiring ICU admission. The mean age was 48 years (range 18–77) and median 46 years; seven patients were male and 6 female. There was a striking increase in the number of cases diagnosed in 2017, with 7 of 13 cases (54%) occurring that year, which coincided with a severe influenza season (Tables 3, 4). Two of the patients presenting in 2017 lived less than 10 kilometres apart and presented to hospital one week apart. No contact tracing was conducted, and the homes of the other patients from 2017 were spread across a broad geographical area. Over half of the affected patients (7 of 13, 54%) were previously well without significant past medical history. Coexisting illnesses in the remaining patients included type 2 diabetes mellitus (3 patients, 23%), asthma (2, 15%), chronic obstructive pulmonary disease (COPD, 1), bronchiectasis (1), lung carcinoma treated with radiotherapy (1) and bipolar disorder (1). Seasonal variation was apparent in that most patients presented in winter (8 of 13, 62%) or early spring [i.e. September] (3 of 13, 23%), with the other two admitted during autumn (Table 5).

Table 5: S.*pyogenes* pneumonia: baseline characteristicsa

| Case | Age/sex | Date admitted | Comorbidities | CXRa consolidation | AKIb | Wbc x 109/Lc | Viral testing multiplex PCRd |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1 | 47/F | 31/8/2007 | Nil | bilateral | yes | 1.9 | negative |
| 2 | 60/M | 19/7/2010 | type 2 diabetes, lung cancer, radiotherapy | lobar | yes | 11.8 | negative |
| 3 | 26/F | 25/9/2010 | bipolar disorder | multilobar | yes | 8.5 | negative |
| 4 | 72/M | 11/8/2014 | nil | bilateral | yes | 5.2 | influenza A |
| 5 | 38/F | 20/5/2015 | nil | lobar | no | 9.7 | negative |
| 6 | 77/M | 9/6/2017 | type 2 diabetes, bronchiectasis | multilobar | yes | 50.6 | RSVe, picornavirus |
| 7 | 38/F | 8/7/2017 | asthma | multilobar, ? empyema | yes | 0.7 | not done |
| 8 | 42/M | 11/8/2017 | nil | lobar, cavitation | yes | 4.0 | influenza A |
| 9 | 58/F | 18/8/2017 | COPD | bilateral | yes | 1.4 | influenza B |
| 10 | 46/M | 25/8/2017 | asthma, type 2 diabetes | lobar | yes | 7.2 | influenza B |
| 11 | 18/F | 8/9/2017 | nil | lobar, ? empyema | no | 101.9 | negative |
| 12 | 58/M | 22/9/2017 | nil | lobar | no | 2.3 | metapneumovirus |
| 13 | 44/M | 24/3/2018 | nil | lobar | no | 16.2 | negative |

a Chest x-ray.

b Acute kidney injury.

c Wbc = white blood count.

d Polymerase chain reaction.

e Respiratory syncytial virus.

## Clinical course

S. pyogenes pneumonia was typically severe, with 12 of 13 (92%) patients admitted to ICU and the mortality rate 17% (2 of 12) when the outcome was known (one patient was transferred to a hospital outside the area without follow-up data). The two fatal cases died within 24 hours of presentation. Mechanical ventilation was required for 67% of patients (8 of 12), inotropic support for 67% (8 of 12) and haemodialysis for 33% (4 of 12). Surgery was undertaken in three patients, thoracotomy and decortication of empyema in two and below knee amputation in one. The mean length of stay for survivors was 28.2 days (range 5–116 days).

## Microbiology

The streptococcal etiology for the S. pyogenes CAP was defined by positive blood cultures in 85% (11 of 13) of patients. Of the 2 patients with negative blood cultures, one had a positive pleural fluid culture for S. pyogenes and the other had Gram positive cocci seen on pleural fluid Gram stain with negative culture but positive 16S rRNA for S. pyogenes (Table 6).

Table 6: S. *pyogenes* pneumonia: clinical course

| Case | ICUa | Ventilation | Inotropes | Positive cultures | Surgery | Mortality |
| --- | --- | --- | --- | --- | --- | --- |
| 1 | yes | unknown | unknown | blood |  | No |
| 2 | yes | yes | yes | blood |  | No |
| 3 | yes | yes | yes | blood | R.BKAb | No |
| 4 | yes | yes | yes | blood |  | Yes |
| 5 | yes | no | no | blood |  | No |
| 6 | yes | yes | yes | pleural fluid 16S rRNAc |  | No |
| 7 | yes | yes | yes | blood | thoracotomy, decortication | No |
| 8 | yes | yes | yes | blood |  | No |
| 9 | yes | yes | yes | blood |  | Yes |
| 10 | yes | yes | yes | blood |  | No |
| 11 | yes | no | no | pleural fluid | VAT,d decortication | No |
| 12 | yes | no | no | blood |  | No |
| 13 | no | no | no | blood |  | No |

a Intensive care unit.

b BKA = below knee amputation.

c Ribosomal deoxyribonucleic acid.

d Video assisted thoracoscopy.

## Other laboratory features

A respiratory viral infection was identified in 50% of patients tested (6 of 12). The viruses identified were influenza A (2), influenza B (2), metapneumovirus (1) and respiratory syncytial virus (RSV) / picornavirus co-infection (1). Four of 13 patients (31%) had leucopenia on presentation (white cell count 0.7–2.3 × 109/L; normal range [NR] 4–11 × 109/L); 2 had marked leucocytosis (50.6, 101.9 × 109/L). A majority of patients (9 of 13, 69%) developed acute kidney injury with serum creatinine at least doubled from baseline.

## Radiology

The chest x-ray for most patients showed extensive consolidation which was multilobar in 3 of 13 (23%) and bilateral in 3 of 13 (23%); rapid progression of consolidation was frequent.

## Non-severe **S. pyogenes** CAP

In addition to the 12 patients with severe S. pyogenes pneumonia requiring ICU admission, only one other patient was identified over the study period of 2007–2018 who was admitted to hospital with S. pyogenes pneumonia of lesser severity (i.e. not requiring ICU admission).

## *S. pyogenes* and severe CAP frequency

There was an increase in the total number of invasive GAS episodes during 2017, with 49 episodes in that year compared to 29 episodes in 2016 and 12 to 25 cases per year in the other years of the study.

The yearly number of cases of severe CAP (defined by ICU admission) ranged from 42 to 77 during the study period. In 2017 there were 73 episodes, which was the third-highest yearly total recorded during 2007–2018.

S. pyogenes accounted for 1.6% (12/728) cases of severe CAP over the course of the study. In 2017, 9.6% (7/73) of the patients with severe CAP had S. pyogenes infection; rates for other years studied were between zero and 2% with the exception of 2010 (3.5%, 2/57).

# Discussion

There have been a number of publications describing rates of invasive S. pyogenes infection (iGAS) in different geographical areas, including data on the proportion of cases due to pneumonia as well as other types of infection (Table 1). The Australian studies were mostly performed in tropical regions with large Aboriginal and Torres Strait Islander populations. A study of iGAS epidemiology was reported from western Sydney although the patient numbers were relatively small.7 Pneumonia has accounted for between 6.6%4 and 10.8%3 of iGAS infections in published studies from different areas of Australia. The overall mortality from iGAS infection has ranged from 7%2 to 13.8%4 in Australian series, with the incidence between 2.1 per 100,000 per year in Victoria6 and 82.5 per 100,000 per year in Aboriginal and Torres Strait Islander people in North Queensland.2 Large series from western Europe and North America have reported the incidence of iGAS infections to range between 1.5 per 100,000 per year8 and 6.3 per 100,000 per year,9 comparable to that reported from Victoria. A consistent finding in larger surveys is that the mortality in GAS pneumonia is about twice that of iGAS infection as a whole.9

There have been several case series of S. pyogenes pneumonia reported in the literature, as well as a literature review which included 16 cases from the past 3 decades. In the current study, the key features (Table 6) include high mortality and about half of the infections occurring in patients without pre-existing medical problems. A further 4 patients with severe S. pyogenes pneumonia have been reported in detail since the above literature review.10–12 Other recent case series described 6 patients requiring ICU treatment for severe S. pyogenes pneumonia over the period 1999–201613 and 3 patients who rapidly died from severe S. pyogenes pneumonia with pulmonary haemorrhage.14

The current study found a lower mortality rate (15%) than did the literature review for S. pyogenes pneumonia (38%)15 or the two largest case series of GAS pneumonia (20%, 47%).16,17 Previous studies showed relatively high proportions of otherwise healthy patients (32 to 63%),15,16 similar to our findings that 6 of 12 (50%) patients with severe S. pyogenes pneumonia lacked significant comorbidities. We found that 50% of patients (6/12) had viral coinfection, which was particularly common during the 2017 upsurge in incidence of S. pyogenes pneumonia (5 of 7 patients tested) and included human metapneumovirus and RSV as well as influenza; the former two viruses have not been described before in association with S. pyogenes pneumonia to our knowledge. The 2017 influenza season reported unprecedented high incidences in New South Wales (Table 3).

We found that S. pyogenes was an uncommon cause of severe CAP, accounting for just 1.6% of 728 episodes over the period 2007–2018, but 9.6% of 73 episodes occurring in 2017. S. pyogenes pneumonia was usually severe, as shown by the requirement for ICU admission in 12 of 13 patients (92%) admitted to hospital. The rate of preceding influenza infection (4/13; 31%) in this study is noteworthy and warrants further investigation from other locations in Australia. The exact pathogenesis of influenza virus predisposing to S. pyogenes pneumonia is not clear but believed to be due to several factors including increased production of fibronectin during influenza infection; increased accessibility of S. pyogenes to bind to fibronectin, facilitated by removal of sialic acid residues from the surfaces of host cells;, and activation of TGF-β by the neuraminidase enzyme. The latter process results in a signalling cascade causing increased fibronectin expression and hence bacterial adherence.18 The protective effect of influenza vaccine on bacterial superinfection and severe bacterial pneumonia is uncertain. Another study showed that influenza vaccine led to enhanced clearance of microorganisms in the superinfected mice and hence suppressed mortality.19

This study is one of the largest case series of adult S. pyogenes pneumonia reported in the literature. We employed a search strategy that maximised the identification of cases of S. pyogenes pneumonia by using multiple sources of data (ICU database for patient identification, pathology database for blood or pleural fluid cultures) and cross-checking with chest x-ray reports and electronic medical records. The ICU database search terms were intentionally broad (e.g. pneumonia, sepsis, respiratory infection) to avoid missing cases. It is possible that some cases of S. pyogenes pneumonia were missed if positive cultures were performed by other pathology services, although the number was expected to be very small. Patients treated in a private hospital may also have been missed. Potential weaknesses of the study included a subjective definition of severe CAP (though used in numerous past studies), the geographically limited study population, not having detailed local data on overall iGAS incidence and the lack of emm-typing of the S. pyogenes isolates.

Likely reasons for the increased incidence of S. pyogenes pneumonia during 2017 may include the increased circulation and infection rates for influenza (Table 3) and other respiratory viruses, changes in circulating strains of S. pyogenes with more virulent strains predominating, and declining community and individual patient antibody titres against the prevalent strains of S. pyogenes. Further molecular analysis of the S. pyogenes isolates was not possible for reasons of funding, but emm-typing may have been helpful to further characterise the local epidemiology of invasive S. pyogenes infection. Specifically, the emergence of a new emm type or increased circulation of an existing emm type with particular tropism for causing pneumonia would have relevance to the community. Results of molecular analysis may also strengthen the case for mandatory public health notification of iGAS episodes, and may contribute toward the potential development of a GAS polyvalent vaccine in the future. To this end, a study which aims to study the local epidemiology of iGAS infection in more detail, with the addition of typing, is underway.

# Conclusion

In the Newcastle area, Streptococcus pyogenes was an uncommon cause of severe community-acquired pneumonia during 2007 to 2018, but a dramatic increase in cases occurred during the severe influenza season in 2017. Viral coinfection occurred in half of the patients with severe S. pyogenes pneumonia, including RSV and human metapneumovirus as well as influenza A and B. Streptococcus pyogenes pneumonia was typically a severe bacteraemic illness with most patients requiring ICU admission and prolonged hospital admission, despite a relatively low age range with many being previously healthy. Further study of the S. pyogenes isolates, including emm typing and more data on S. pyogenes CAP and overall iGAS incidence in NSW, may help our understanding of the local epidemiology of this severe infection.

# Author details

Paul A.Wilson1

Hemalatha Varadhan2

1. Staff specialist physician, Calvary Mater Newcastle, Waratah, New South Wales, Australia
2. Clinical microbiologist, Pathology North – Hunter, NSW Pathology, New South Wales, Australia

# Corresponding author

Dr Paul A.Wilson

Calvary Mater Newcastle, Department of Medicine, Edith St, Waratah NSW 2298, Australia.

Phone: 0413 243358

E-mail: paul.wilson@calvarymater.org.au

# References

1. Morens DM, Taubenberger JK. A forgotten epidemic that changed medicine: measles in the US Army, 1917-18. Lancet Infect Dis. 2015;15(7):852–61.
2. Norton R, Smith HV, Wood N, Siegbrecht E, Ross A, Ketheesan N. Invasive group A streptococcal disease in North Queensland (1996–2001). Indian J Med Res. 2004;119(Suppl):148–51.
3. O’Grady K, Kelpie L, Andrews RM. The epidemiology of invasive group A streptococcal disease in Victoria, Australia. Med J Aust. 2007;186(11): 565–9.
4. Gear RJ, Carter JC, Carapetis JR, Baird R, Davis JS. Changes in the clinical and epidemiological features of group A streptococcal bacteraemia in Australia’s Northern Territory. Trop Med Int Health. 2015;20(1):40–7.
5. Boyd R, Patel M, Currie BJ, Holt DC, Harris T, Krause V. High burden of invasive group A streptococcal disease in the Northern Territory of Australia. Epidemiol Infect. 2016;144(5):1018–27.
6. Oliver J, Wilmot M, Strachan J, St George S, Lane CR, Ballard SA et al. Recent trends in invasive group A Streptococcus disease in Victoria. Commun Dis Intell (2018). 2019;43. doi: ttps://doi.org/10.33321/cdi.2019.43.8.
7. Sivagnanam S, Zhou F, Lee AS, O’Sullivan MVN. Epidemiology of invasive group A Streptococcus infections in Sydney, Australia. Pathology. 2015;47(4):365–71.
8. Davies HD, McGeer A, Schwartz B, Green K, Cann D, Simor AE et al. Invasive group A streptococcal infections in Ontario, Canada. N Engl J Med. 1996; 335(8):547–54.
9. Tyrrell GJ, Lovgren M, St Jean T, Hoang L, Patrick DM, Horsman G et al. Epidemic of group A Streptococcus M/emm59 causing invasive disease in Canada. Clin Infect Dis. 2010;51(11):1290–7.
10. Mori N, Hosoo S, Oyamada Y, Sera Y, Yamada Y, Sugawara M et al. Characteristics of mucoid Streptococcus pyogenes isolated from two patients with pneumonia in a local community. IDCases. 2016;6:43–6.
11. Sakai T, Taniyama D, Takahashi S, Nakamura M, Takahashi T. Pleural empyema and streptococcal toxic shock syndrome due to Streptococcus pyogenes in a healthy Spanish traveler in Japan. IDCases. 2017;9:85–8.
12. Chen M, Wang W, Tu L, Zheng Y, Pan H, Wang G et al. An emm5 group A streptococcal outbreak among workers in a factory manufacturing telephone accessories. Front Microbiol. 2017;8:1156. doi: http://doi.org/10.3389/fmicb.2017.01156.
13. Lecronier M, Elabbadi A, Mekontso Dessap A, de Prost N. Short and long-term outcomes of Streptococcus pyogenes pneumonia managed in the intensive care unit. Infect Dis (Lond). 2017;49(10):775–7.
14. Santagati N, Spanu T, Scillato M, Santangelo R, Cavallaro F, Arena V et al. Rapidly fatal hemorrhagic pneumonia and group A Streptococcus serotype M1. Emerg Infect Dis. 2014;20(1):98–101.
15. Akuzawa N, Kurabayashi M. Bacterial pneumonia caused by Streptococcus pyogenes infection: a case report and review of the literature. J Clin Med Res. 2016;8(11):831–5.
16. Barnham M, Weightman N, Anderson A, Pagan F, Chapman S. Review of 17 cases of pneumonia caused by Streptococcus pyogenes. Eur J Clin Microbiol Infect Dis. 1999;18(7):506–9.
17. Tamayo E, Montes, Vicente D, Pérez-Trallero E. Streptococcus pyogenes pneumonia in adults: clinical presentation and molecular characterization of isolates 2006–2015. PLoS One. 2016;11(3):e0152640. doi: https://doi.org/10.1371/journal.pone.0152640.
18. Herrera AL, Faal H, Moss D, Addengast L, Fanta L, Eyster K et al. The Streptococcus pyogenes fibronectin/tenascin-binding protein PrtF.2 contributes to virulence in an influenza superinfection. Sci Rep. 2018;8(1);12126. doi: https://doi.org/10.1038/s41598-018-29714-x.
19. Okamoto S, Kawabata S, Fujitaka H, Uehira T, Okuno Y, Hamada S. Vaccination with formalin-inactivated vaccine protects mice against lethal influenza Streptococcus pyogenes superinfection. Vaccine. 2004;22(21–22):2887–93.
20. Scaber J, Saeed S, Ihekweazu C, Efstratiou A, McCarthy N, O’Moore E. Group A streptococcal infections during the seasonal influenza outbreak 2010/11 in South East England. Euro Surveill. 2011;16(5). pii: 19780.
21. Jean C, Louie LK, Glaser CA, Harriman K, Hacker JK, Aranki F et al. Invasive group A streptococcal infection concurrent with 2009 H1N1 influenza. Clin Infect Dis. 2010;50(10):e59–62.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Tanja Farmer

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, John Kaldor, Martyn Kirk and Linda Selvey

**Website**: <http://www.health.gov.au/cdi>

**Contacts**Communicable Diseases Intelligence is produced by:
Health Protection Policy Branch, Office of Health Protection, Australian Government Department of Health
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** cdi.editor@health.gov.au

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: cdi.editor@health.gov.au.

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2020 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: copyright@health.gov.au

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.
<http://www.health.gov.au/cdna>